Johnson & Johnson (NYSE:JNJ) announced promising results from a mid-stage trial evaluating a combination of Tecvayli (teclistamab) and Darzalex Faspro (daratumumab and hyaluronidase) for the treatment of multiple myeloma.
The study, which involved 49 patients placed in three groups, showed an overall response of 100% after the first round of treatment.
By the sixth treatment cycle, nearly 86% of patients had achieved a complete or very deep response, with no signs of detectable disease.
JNJ added that safety results confirmed the therapy was generally well tolerated.
